BERKELEY, Calif.–(BUSINESS WIRE)– #AIDrugDiscovery–Bifrost Biosystems today announced that it has secured a commercial supply agreement with Illumina enabling integration of Illumina’s industry-standard sequencing-by-synthesis (SBS) chemistry into its optical pooled screening (OPS) platform slated to be commercially available in early 2027. OPS is a technology to link complex cellular phenotypes to the responsible genetic perturbation cost-effectively and at scale.The agreement provides reliable access to high-
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
